Identification and purification of the Holo-ELL complex. Evidence for the presence of ELL-associated proteins that suppress the transcriptional inhibitory activity of ELL.

The Journal of Biological Chemistry
A Shilatifard

Abstract

The human ELL gene on chromosome 19 undergoes frequent translocation with the trithorax-like MLL gene on chromosome 11 in acute myeloid leukemia. Recently, it was demonstrated that the product of the human ELL gene encodes an RNA polymerase II elongation factor (Shilatifard, A., Lane, W. S., Jackson, K. W., Conaway, R. C., and Conaway, J. W. (1996) Science 271, 1873-1876). In addition to its elongation regulatory activity, ELL contains a novel type of RNA polymerase II interaction domain that is capable of negatively regulating polymerase activity in promoter-specific transcription in vitro (Shilatifard, A., Haque, D., Conaway, R. C., and Conaway, J. W. (1997) J. Biol. Chem. 272, 22355-22363). Here, we report the identification and purification of a large ELL-containing complex that contains three proteins in addition to ELL and that we have named the Holo-ELL complex. The Holo-ELL complex can increase the catalytic rate of transcription elongation by RNA polymerase II. However, unlike the ELL polypeptide alone, the Holo-ELL complex is not capable of negatively regulating polymerase activity in promoter-specific transcription in vitro. The inability of the Holo-ELL complex to negatively regulate polymerase activity in promoter-...Continue Reading

References

May 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·G A RiceM J Chamberlin
Nov 10, 1994·Nature·T H Rabbitts
Dec 6, 1994·Proceedings of the National Academy of Sciences of the United States of America·M J ThirmanJ D Rowley
Mar 29, 1996·Science·A ShilatifardJ W Conaway
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·R PrasadE Canaani

❮ Previous
Next ❯

Citations

Aug 1, 2000·Trends in Biochemical Sciences·J W ConawayR C Conaway
Sep 16, 2006·Journal of Virology·Charles LangelierWesley I Sundquist
Jun 29, 2000·Annual Review of Biochemistry·J W Conaway, R C Conaway
Oct 13, 2009·FEBS Letters·Amit MathewsKrassimir Yankulov
Jun 23, 2007·European Journal of Cell Biology·Iwona PileckaMarta Miaczynska
Oct 1, 2003·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Min LiYi-Hsin Liu
Mar 13, 2010·Biology of the Cell·Ingrid RoxrudLene Malerød
May 24, 2006·Trends in Cell Biology·Thomas SlagsvoldHarald Stenmark
Jul 7, 2009·Molecular Oncology·Beata PyrzynskaMarta Miaczynska
Feb 3, 2007·Nature·Tor Erik Rusten, Harald Stenmark
Feb 3, 2012·Physiological Reviews·Sara SigismundPier Paolo Di Fiore
Jan 22, 2013·Genetics·Naseem A GaurAlan G Hinnebusch
Nov 7, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A Shilatifard
Mar 11, 2020·Proceedings of the National Academy of Sciences of the United States of America·Subham BasuDebabrata Biswas
Oct 16, 2019·Proceedings of the National Academy of Sciences of the United States of America·Nidhi KumariDebabrata Biswas
Apr 30, 2020·Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms·Subham BasuDebabrata Biswas
Oct 19, 2004·Genes & Development·Robert J SimsDanny Reinberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.